NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Harrow, Inc. HROW
19 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 272.3M
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 272.3 · Net income -5.1
Compound annual growth
Revenue compounded at +41.0% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−2 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating 11.2% · Net -1.9%
ROE
FY2025 · ROE -8.4%
Each USD of equity lost 8 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · |
| Operating income $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | −0.0 | −0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | 0.0 | −0.0 | 0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EPS, diluted $ | −0.14 | −0.49 | −0.75 | −0.51 | −0.69 | −0.13 | 0.01 | 0.61 | −0.60 | −1.50 | −1.66 | −1.11 | −0.88 | −1.24 | −2.65 | −0.16 | · | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −8.4 | −24.9 | −49.6 | −72.5 | −93.6 | −12.2 | 0.6 | 106.9 | −264.9 | −756.4 | −470.0 | −87.0 | −60.9 | −129.8 | · | · | −176.9 | −82.0 | −122.7 |
| Shares out B | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.02 | · | · | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 75 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 20 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007